Literature DB >> 34225815

Quantified assessment of deep brain stimulation on Parkinson's patients with task fNIRS measurements and functional connectivity analysis: a pilot study.

Ningbo Yu1,2, Siquan Liang3, Jiewei Lu1,2, Zhilin Shu1,2, Haitao Li3, Yang Yu4, Jialing Wu5,6,7, Jianda Han8,9.   

Abstract

BACKGROUND: Deep brain stimulation (DBS) has proved effective for Parkinson's disease (PD), but the identification of stimulation parameters relies on doctors' subjective judgment on patient behavior.
METHODS: Five PD patients performed 10-meter walking tasks under different brain stimulation frequencies. During walking tests, a wearable functional near-infrared spectroscopy (fNIRS) system was used to measure the concentration change of oxygenated hemoglobin (△HbO2) in prefrontal cortex, parietal lobe and occipital lobe. Brain functional connectivity and global efficiency were calculated to quantify the brain activities.
RESULTS: We discovered that both the global and regional brain efficiency of all patients varied with stimulation parameters, and the DBS pattern enabling the highest brain efficiency was optimal for each patient, in accordance with the clinical assessments and DBS treatment decision made by the doctors.
CONCLUSIONS: Task fNIRS assessments and brain functional connectivity analysis promise a quantified and objective solution for patient-specific optimization of DBS treatment. TRIAL REGISTRATION: Name: Accurate treatment under the multidisciplinary cooperative diagnosis and treatment model of Parkinson's disease. Registration number is ChiCTR1900022715. Date of registration is April 23, 2019.

Entities:  

Keywords:  Brain efficiency; Deep brain stimulation programming; Functional connectivity; Parkinson’s disease

Year:  2021        PMID: 34225815     DOI: 10.1186/s41016-021-00251-3

Source DB:  PubMed          Journal:  Chin Neurosurg J        ISSN: 2057-4967


  41 in total

Review 1.  Exploring the brain network: a review on resting-state fMRI functional connectivity.

Authors:  Martijn P van den Heuvel; Hilleke E Hulshoff Pol
Journal:  Eur Neuropsychopharmacol       Date:  2010-05-14       Impact factor: 4.600

Review 2.  Parkinson's disease: clinical features and diagnosis.

Authors:  J Jankovic
Journal:  J Neurol Neurosurg Psychiatry       Date:  2008-04       Impact factor: 10.154

Review 3.  Parkinson's disease. Second of two parts.

Authors:  A E Lang; A M Lozano
Journal:  N Engl J Med       Date:  1998-10-15       Impact factor: 91.245

Review 4.  Deep brain stimulation.

Authors:  Joel S Perlmutter; Jonathan W Mink
Journal:  Annu Rev Neurosci       Date:  2006       Impact factor: 12.449

Review 5.  Deep brain stimulation for Parkinson's disease.

Authors:  Alim Louis Benabid
Journal:  Curr Opin Neurobiol       Date:  2003-12       Impact factor: 6.627

6.  Biomarkers for closed-loop deep brain stimulation in Parkinson disease and beyond.

Authors:  Walid Bouthour; Pierre Mégevand; John Donoghue; Christian Lüscher; Niels Birbaumer; Paul Krack
Journal:  Nat Rev Neurol       Date:  2019-06       Impact factor: 42.937

Review 7.  Gene-environment interactions in psychiatry: joining forces with neuroscience.

Authors:  Avshalom Caspi; Terrie E Moffitt
Journal:  Nat Rev Neurosci       Date:  2006-07       Impact factor: 34.870

Review 8.  Deep Brain Stimulation Programming for Movement Disorders: Current Concepts and Evidence-Based Strategies.

Authors:  Thomas Koeglsperger; Carla Palleis; Franz Hell; Jan H Mehrkens; Kai Bötzel
Journal:  Front Neurol       Date:  2019-05-21       Impact factor: 4.003

Review 9.  Deep brain stimulation: current challenges and future directions.

Authors:  Andres M Lozano; Nir Lipsman; Hagai Bergman; Peter Brown; Stephan Chabardes; Jin Woo Chang; Keith Matthews; Cameron C McIntyre; Thomas E Schlaepfer; Michael Schulder; Yasin Temel; Jens Volkmann; Joachim K Krauss
Journal:  Nat Rev Neurol       Date:  2019-03       Impact factor: 42.937

Review 10.  Chinese expert consensus on programming deep brain stimulation for patients with Parkinson's disease.

Authors:  Shengdi Chen; Guodong Gao; Tao Feng; Jianguo Zhang
Journal:  Transl Neurodegener       Date:  2018-04-30       Impact factor: 8.014

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.